New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program
In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progression-free survival observed to date in first-line EGFR exon20ins NSCLC
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Moderna, Inc. to Join the Nasdaq-100 Index® Beginning October 9, 2026
- Carta de ZenaTech a los accionistas destaca un crecimiento del 316% de los ingresos en el segundo trimestre y el séptimo trimestre consecutivo de crecimiento secuencial
- Medicenna Announces Results of Annual General and Special Meeting of Shareholders
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,400+ feeds — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →